TrialFuture oncology (London, England)2024

Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.

Xi Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.